Edition:
United Kingdom

Celyad SA (CYAD.OQ)

CYAD.OQ on NASDAQ Stock Exchange Global Market

35.81USD
14 Dec 2017
Change (% chg)

$-5.44 (-13.19%)
Prev Close
$41.25
Open
$40.76
Day's High
$40.98
Day's Low
$35.13
Volume
6,651
Avg. Vol
1,392
52-wk High
$64.00
52-wk Low
$17.24

Summary

Name Age Since Current Position

Michel Lussier

52 2007 Chairman of the Board, Co-Founder

Christian Homsy

57 2007 Member of the Executive Management Committee, Chief Executive Officer, Executive Director

Patrick Jeanmart

43 2007 Member of the Executive Management Committee, Chief Financial Officer

Gaetane Metz

2013 Chief Operating Officer

Richard Mountfield

2016 Vice President of Global Regulatory Affairs

Peter De Waele

56 Member of the Executive Management Committee, Vice President - Research & Development

Georges Rawadi

2014 Vice President - Business Development

Seron Aymeric

2012 Program Manager

Philippe Dechamps

2016 Chief Legal Officer

Roland Gordon-Beresford

2008 Regulatory Affairs and IP Director

Jaak Minten

2012 Director Clinical Affairs, representing Fakkel SPRL

Anne Portzenheim

2010 Communication Manager

Serge Goblet

Non-Executive Director

Hanspeter Spek

67 2014 Non-Executive Director

William Wijns

Non-Executive Director, permanent representative of the Cardiovascular Center Aalst CVBA

Chris Buyse

Independent Director, permanent representative of Life Sciences Research Partners

Rudy Dekeyser

Independent Director

Jean-Marc Heynderickx

Independent Director

Louise Proulx

2012 Independent Director

Biographies

Name Description

Michel Lussier

Mr. Michel E. Lussier has served as Chairman of the Board and Co-Founder since Cardio3 Biosciences SA inception in July 2007. He obtained a degree of Bachelor of Sciences in Electrical Engineering and a degree of Master in Sciences in Biomedical Engineering at the University of Montreal. He also holds a Masters of Business Administration from INSEAD (European Institute of Business Administration), France. He was also co-Founder and Chairman of the Board of Directors of the Company’s predecessor entity, Cardio3 SA, from its incorporation in 2003 until its liquidation in 2008. From September 1994 until its acquisition by Guidant in 1998, Michel led, as Vice-President and General Manager of European Operations, the European subsidiary of InControl Corp. From October 1998 to March 2002, Michel served as Vice President, General Manager Europe of Novoste Corp. From July 2002 to 2007, he assumed the position of Volcano Vice President, General Manager of Europe, Africa and Middle East for Volcano Corporation. From 2007 until October 2012, he served as Volcano Group President, Advanced Imaging Systems, Global Clinical & Scientific Affairs and General Management of Europe, Africa and Middle East. Since October 2012, he serves as President, Clinical and Scientific Affairs for Volcano. In February 2002, he founded Medpole SA. He brings 15 years of operational experience with Medtronic Inc, where he led the company's core business in Europe as Business Director Cardiac Pacing. Additionally, Mr. Lussier is Chief Executive Officer of Medpole SA and has been Chairman of a number of committees within Eucomed. He also served on several start-up boards for medical devices. He is Member of the Company's Nomination and Remuneration Committee.

Christian Homsy

Mr. Christian Homsy has served as Member of the Executive Management Committee, Chief Executive Officer and Executive Director of Cardio3 Biosciences SA since July 2007. He obtained his Medical Doctorate at the University of Louvain and holds an Masters of Business Administration from the IMD in Lausanne (Switzerland). He has been Chief Executive Officer of Cardio3 the Company since its foundation. He gained his business experience in senior research and development, marketing, business development and sales positions at Guidant Corporation. He was also founder of Guidant Institute for Therapy Development, a landmark facility for physician and health care professionals' education that gained international recognition and praise. Christian excelled in building businesses with well-respected teams, setting standards inside and outside the organization. Before joining the Company, Mr. Homsy was General Manager of Medpole, a European incubator dedicated to initiating the European operations for start-up companies in the medical device or biotechnology fields. He also holds a director mandate in Medpole SA.

Patrick Jeanmart

Mr. Patrick Jeanmart has been Member of the Executive Management Committee and Chief Financial Officer of Cardio3 Biosciences SA since September 2007. Mr. Jeanmart obtained a Master in Economics from the University of Namur, Belgium. He has served as Chief Financial Officer since September 2007. Prior to joining the Company, he worked for IBA (Ion Beam Applications, Belgium) during six years where he held a number of senior financial management positions within several IBA subsidiaries located in Belgium, Italy, United Kingdom and the United States. Between January 2004 and 2007, Patrick acted as Vice President of Finance of IBA Molecular. He also holds the position of Chief Financial Officer at Medpole SA and at Biological Manufacturing Services SA.

Gaetane Metz

Richard Mountfield

Dr. Richard Mountfield has served as Vice President of Global Regulatory Affairs of CELYAD S.A. since February 3, 2016. Richard is a pharmaceutical professional with extensive Regulatory Affairs (preclinical, clinical, registration, and post-marketing) & Drug Development experience including leadership, management and project roles. Prior to joining Celyad he held positions in Europe and the US for a number of top 20 Pharmaceutical companies (Novo Nordisk, Roche, Boehringer Ingelheim and Novartis). He has been responsible for global regulatory strategy and submissions across a number of therapeutic areas. Most recently he was the global regulatory lead responsible for developing and implementing approvable strategies for a large multi-indication oncology program within Novartis. Richard holds a PhD in Biochemistry from Aberystwyth University.

Peter De Waele

Dr. Peter De Waele is Member of the Executive Management Committee and Vice President - Research & Development of Cardio3 Biosciences SA. He obtained his Master of Science in Biochemistry and Physiology at Ghent University, Belgium. He holds a Doctoral degree in Molecular Biology at the department of Molecular Biology headed by Professor Walter Fiers at the same university, where he was assistant professor until 1986. He has been serving as Vice President Research & Development since November 2010. Dr. De Waele not only brings his clinical experience to the Company, he has also years of business experience. He has been a consultant to the pharmaceutical and biotech industry since 2006, with a particular focus on adult stem cell product development for different therapeutic indications. Up to 2006, Dr. De Waele worked as Chief Operating Officer at XCELLentis NV, a biotech company developing stem cell based therapies and medical devices for wound healing. Before founding XCELLentis in 2001, he held several senior management positions at Innogenetics NV As Chief Therapeutics Officer of Innogenetics and as Chief Operating Officer of XCELLentis he was responsible for several multicenter international clinical trials with recombinant vaccines and cell derived advanced medical products. Moreover, Dr. De Waele also assumes the function of Managing Director in Advanced Therapies Consulting Limited. He is also consultant for regulatory affairs, quality assurance and quality control and research & development at Cryo-Save AG in Switzerland as well as acting as Responsible Person for the Dutch tissue bank Stichting Cryo-Save.

Georges Rawadi

Dr. Georges Rawadi has been appointed as Vice President Business Development at Cardio3 BioSciences SA as of June 2, 2014. Dr. Rawadi will be responsible for leading C3BS` worldwide business development efforts, by identifying avenues for growth, international expansion and managing the company`s business partner relationships. Prior to joining C3BS, Dr. Rawadi served as Vice President Business Development with Cellectis. He previously held business development management positions at Galapagos, ProStrakan France and Sanofi-Aventis France, and conducted consultancy assignments in Business Development and Alliance Management. His work included all aspects and stages of business development, driving several projects from target identification and negotiation to closing deals. Dr. Rawadi holds a PhD in Microbiology from the Pierre et Marie Curie University (France), and a Masters in Management and Strategy in the Health Industry from the ESSEC Business School.

Seron Aymeric

Mr. Seron Aymeric is Program Manager of Cardio3 Biosciences SA since the beginning of 2012. He has more than 10 years experience in medical device for percutaneous therapy (embolization, drug eluting stent, catheters) and in Advanced Therapy Medicinal Product (ATMP). He has overall responsibility of C-Cathez (endocardial injection catheter) and C3BS-CQR-1 (cell based therapy) programs. He holds a Master in Sciences / Engineer Degree and a Doctorate in Philosophy in Biomaterials field.

Philippe Dechamps

Roland Gordon-Beresford

Mr. Roland Gordon-Beresford, Ph.D., has served as Regulatory Affairs and IP Director of Cardio3 Biosciences SA since January 2008. He brings to the Company15 years of experience in managing registrational strategies and processes with pharmaceutical, medical technology and biotechnology products, acquired at Bristol-Myers Squibb Int. Corp. and Navigant Biotechnologies among others. He holds a Doctorate in Philosophy in Molecular Biology from the Free University of Brussels, Belgium.

Jaak Minten

Mr. Jaak Minten is Director Clinical Affairs, representing Fakkel SPRL, of Cardio3 Biosciences SA since January 2012. He brings to C3BS experience in Clinical Research. Prior to joining the Company, he acted as Clinical Director with Medtronic where he was responsible for the strategic setting and implementation of clinical trials in Europe for a variety of medical device products, incl. cell therapy and TAVI.

Anne Portzenheim

Ms. Anne Portzenheim has served as Communication Manager at Cardio3 Biosciences SA since January 2010. She combines 22 years of Sales, Marketing and Communication experience. She has responsibility for all areas related to external and internal communication such as strategic communication plans, Press and Media Relations, website, congress organization. Prior to joining the Company, she was employed at Beiersdorf as Media, Direct Marketing and Internet Manager. She holds a Master of Arts in Applied Economic Sciences from the University of Louvain, Belgium (Katholieke Universiteit Leuven).

Serge Goblet

Mr. Serge Goblet is Non-Executive Director at Cardio3 Biosciences SA. He holds a Master Degree in Business and Consular Sciences (“licence en sciences commerciales et consulaires”) from ICHEC, Belgium and has many years of international experience as Director in Belgian and foreign companies. He is Managing Director of TOLEFI SA, a Belgian holding company and holds Director mandates in subsidiaries of Tolefi.

Hanspeter Spek

Mr. Hanspeter Spek was appointed as a Non-Executive Member of the Board of Directors of Cardio3 Biosciences SA as of May 5, 2014. He started his career at Pfizer where, over more than 10 years and after a training in commercial general management, he held positions of increasing responsibility. He then joined Sanofi as Marketing Director and rose through the organization to become the Executive Vice President International in 2000. When Sanofi and Aventis merged in 2004, he took on the responsibility of Executive Vice President Operations. In 2009, he was nominated President Global Operations. He retired from Sanofi in mid-2013. He has since joined Advent as a Senior Advisor for Healthcare. He continues to serve on the Board of Sanofi, Germany, as Chairman.

William Wijns

Dr. William Wijns is Non-Executive Director, permanent representative of the Cardiovascular Center Aalst CVBA, of Cardio3 Biosciences SA. Dr. William Wijns graduated in 1976 from the University of Louvain in Belgium where he trained as a cardiologist until 1981. He then joined the Thorax Center in Rotterdam, the Netherlands, where he was actively involved with the first applications of nuclear cardiology, thrombolysis and coronary dilatation. After spending two years as a Visiting Associate Professor of Radiological Sciences at UCLA, Mr. Wijns returned to the University of Louvain in Brussels where he directed the cardiac PET program and became Clinical Professor of Cardiology. His research focused on the regulation of coronary blood flow and cardiac metabolism in ischemic heart disease. Since 1994, Dr. Wijns is the co-Director of the Cardiovascular Center Aalst and merely active as an interventional cardiologist. More recently, he has been involved with the clinical applications of non-invasive coronary angiography with the use of multislice computed tomography. He has authored over 300 publications in peer-reviewed journals and holds several positions in national and international professional and scientific organizations. Dr. Wijns is also a Board member of the World Heart Federation and the European Society of Cardiology (Chairperson European Relations Committee 2008-2010). Since September 2006, he is President of EAPCI, the European Association for Percutaneous Cardiovascular Interventions.

Chris Buyse

Mr. Chris Buyse is Independent Director, permanent representative of Life Sciences Research Partners, of Cardio3 Biosciences SA. Mr. Buyse holds a master degree in applied economic sciences from the University of Antwerp and a Masters of Business Administration from Vlerick School of Management in Gent. He brings to Cardio3 BioSciences more than 20 years of international financial knowledge and experience in introducing financial management practices. Since August 2006 he is Chief Financial Officer and director of ThromboGenics NV. Before joining ThromboGenics, he was Chief Financial Officer of the Belgian biotech company CropDesign, where he coordinated the acquisition by BASF in July 2006. Prior to joining CropDesign he was financial manager of WorldCom/MCI Belux and he was also Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies. In addition he also held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever. He currently serves, in his own name or as permanent representative of a management company, as member of the board of directors of the following privately held companies:, Bone Therapeutics SA, Iteos SA, Q-Biologicals NV, Immo David NV, Pinnacle Investments SA, CreaBuild NV and Pienter-Jan BVBA, ThromboGenics NV, Life Sciences Research Partners VZW (a shareholder of the Company) and Keyware Technologies NV. He is Member of the Company's Nomination and Remuneration Committee.

Rudy Dekeyser

Mr. Rudy Dekeyser is Independent Director at Cardio3 Biosciences SA. Mr. de Keyser obtained a Doctorate in Philosophy in Molecular Biology at the University Ghent. Since 2012 he is Managing Partner of the LSP Health Economics Fund, a private equity fund investing in late stage European and North American health care companies. Prior to joining LSP, he has been Managing Director of VIB (Flanders Institute for Biotechnology), managing for more than 16 years. He holds Non-Executive Director position Remynd NV, and held Non-Executive Director positions until recently in Devgen NV, CropDesign NV, Ablynx NVActogenix NV, Pronota NV, Flandersbio VZW, Bioincubator Leuven NV, Biolign NV and Multiplicom NV. He is Co-Founder of ASTP (the European associations of technology transfer managers) and Chairman of EMBLEM and of the valorisation board of NGI (the Dutch genome initiative). He has been advisor to several seed and venture capital funds and to multiple regional and international committees on innovation. He is Member of the Company's Nomination and Remuneration Committee.

Jean-Marc Heynderickx

Mr. Jean-Marc Heynderickx is Independent Director of Cardio3 Biosciences SA. With a degree in Marketing from Charleroi University (Belgium). Mr. Heynderickx spent his career in the Louis Delhaize Group and was Chief Executive Officer from 1995 to 2010. As such, he was also Chairman of sub holding companies in France, Luxemburg and in The Netherlands. From 2000 to 2005, he was Board Member of Comeos ( Fedis ) national retail organization and Charleroi Chamber of Commerce. In 2005, Mr. Heynderickx completed the Solvay executive program in Real Estate. He is now Chief Executive Officer of Nextgen group. He is currently also Board Member of FRI (First Retail International) a Belgian Investment funds specialized in Retail Warehousing. In 2006 he was Co-Founder of the Budapest Food Bank.

Louise Proulx

Dr. Louise Proulx, Ph.D., is Independent director at Cardio3 Biosciences SA since 2012. Ms. Proulx holds a Doctorate in Philosophy in Physiology from Universite Laval (Canada) and pursued postdoctoral studies at Karolinska Institutet. She has nearly 30 years of experience in research and science management. She currently holds the position of Vice-President, Research and Development, and Site Head, at Vertex Pharmaceuticals Incorporated (Canada), and has also held positions at Topigen Pharmaceuticals Inc., ViroChem Pharma Inc, Hoechst Marion Roussel and BioChem Pharma Inc. Outside of the pharmaceutical industry, Dr. Proulx has served as Vice-President, Business Development of Genome Quebec and Vice Principal Research at McGill University. Dr. Proulx has been Member of several Board of Directors including the National Research Council of Canada. She is currently Member of the Board of Directors of Diagnocure Inc., Genome Quebec and the Canada Foundation for Innovation.